A cell surface receptor called Programmed Death-1 (PD-1) serves as a T cell checkpoint and is crucial in controlling T cell exhaustion. PDL-1 or PDL-2 engagement with PD-1 causes it to become active. When the PD-1 receptor binds to its ligands, PD-L1 and PD-L2, which are expressed on cancer cells and antigen-presenting cells, it sends inhibitory checkpoint signals to activated T cells. This suppresses T-cell effector function and allows tumor immune evasion. An appealing approach for tumor immunotherapy is to block the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway.
Activated T cells, B cells, monocytes, dendritic cells, regulatory T cells, and natural killer T cells all express PD-1. It belongs to a group of immunoglobulin domain (Ig) co-receptors that affect how the T cell receptor responds when activated by an antigen-presenting cell (APC) or an infected target cell. In contrast to PD-L2, which is only and inducibly expressed on professional APCs, PD-L1 is widely expressed and constitutively on both hematopoietic and nonhematopoietic cells, including naive T and B cells, vascular endothelial cells, and pancreatic islet cells.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V75224 | Ezabenlimab (BI-754091) | 2249882-54-8 | Ezabenlimab (BI-754091) is an anti-PD-1 monoclonal antibody (mAb) that binds PD-1 with a Kd of 6 nM (CHO cells). |
|
V21365 | Fraxinellone | 28808-62-0 | Fraxinellone is a naturally occurring anti-inflammatory agentisolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. |
|
V75211 | Geptanolimab (APL-501; CBT-501; GB-226) | 2348469-43-0 | Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody (mAb) directed against programmed death-1 (PD-1). |
|
V75217 | Gilvetmab | 1808081-43-7 | Gilvetmab is a potent canine-derived anti-PD-1 monoclonal antibody (mAb). |
|
V75241 | Human membrane-bound PD-L1 polypeptide | 1831010-13-9 | Human membrane-bound PD-L1 polypeptide can serve as an antigen to induce the production of PD-L1 antibodies. |
|
V75232 | Human PD-L1 inhibitor I | 2135542-86-6 | Human PD-L1 inhibitor I is an hPD-1 peptide ligand with a Kd of 3.39 μM. |
|
V75235 | Human PD-L1 inhibitor II | 2135542-85-5 | Human PD-L1 inhibitor II is a potent PD-L1 inhibitor (antagonist) with anti-cancer activity. |
|
V74274 | Human PD-L1 inhibitor III | 2135542-84-4 | Human PD-L1 inhibitor III is an inhibitor (blocker/antagonist) of human PD-L1. |
|
V75216 | Human PD-L1 inhibitor IV | 2135542-83-3 | Human PD-L1 inhibitor IV is a competitive human PD-1 protein inhibitor (antagonist) with a Kd of 1.38 μM, which can inhibit the binding of human PD-1/PD-L1. |
|
V75233 | Human PD-L1 inhibitor V | 2815311-61-4 | Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd of 3.32 μM, which can inhibit the binding of human PD-1/PD-L1. |
|
V4418 | INCB086550 | 2230911-59-6 | INCB-086550 (INCB-086550) is a novel, investigational and selective small moleculePD-1/PD-L1 inhibitor based on the biphenyl scaffold core structure first disclosed by BMS company. |
|
V75250 | Iparomlimab | 2417649-33-1 | Iparomlimab is an IgG4κ antibody against human PD-1/CD279/PDCD1. |
|
V75239 | Izuralimab | 2329669-80-7 | Izuralimab is a bispecific IgG1 antibody targeting inducible T cell costimulator (ICOS/CD278) and PD-1. |
|
V75238 | Latika fusp (AMG 256) | 2552814-07-8 | Latikafusp (AMG 256) is a bifunctional fusion protein containing an antibody targeting PD-1 and an IL-21 mutant protein designed to provide IL-21 pathway stimulation to PD-1+ cells. |
|
V74277 | Lipustobart (lipusubinumab) | 2639481-06-2 | Lipstobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody (mAb). |
|
V75248 | Lodapolimab (LY3300054) | 2118349-31-6 | Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody (mAb). |
|
V74877 | Lorigerlimab (MGD019) | 2416595-46-3 | Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity retargeting antibody (DART). |
|
V75243 | Manelimab (BCD-135) | 2168561-26-8 | Manelimab is a monoclonal antibody (mAb) that can inhibit programmed death ligand 1 (PD-L1). |
|
V4375 | NIVOLUMAB | 946414-94-4 | Nivolumab (BMS-936558; ONO-4538; MDX-1106;Opdivo) is a programmed death receptor-1 (PD-1) blocking antibody, known also as therapeutic antibody of PD-1, that has been approved for use to treat advanced (metastatic) non-small cell lung cancer. |
|
V75246 | Nofazinlimab (CS1003) | 2377845-98-0 | Nofazinlimab (CS1003) is a human IgG4 anti-PD-1 monoclonal antibody (mAb). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
